Neverfail

neverfail.com

Neverfail enables IT to meet or exceed service level agreements (SLAs) by providing continuous availability and connectivity to applications, data, and infrastructure. We do this by providing bullet-proof technology, industry-leading experience, and a complete dedication to customer success.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

WUXI ATU AND WUGEN ANNOUNCE MANUFACTURING PARTNERSHIP TO EXPEDITE THE DELIVERY OF NOVEL CELL CANCER IMMUNOTHERAPIES

Wugen | June 16, 2022

news image

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...

Read More

Industrial Impact

MODERNA AND THERMO FISHER SCIENTIFIC ANNOUNCE LONG-TERM STRATEGIC COLLABORATION

Moderna, Inc. | February 24, 2022

news image

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc. the world leader in serving science, today announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline. “Thermo Fisher continues to be a trusted partner, bringing a ...

Read More

Industrial Impact, Medical

BICYCLE THERAPEUTICS ANNOUNCES A STRATEGIC COLLABORATION WITH NOVARTIS TO DISCOVER, DEVELOP AND COMMERCIALIZE BICYCLE® RADIO-CONJUGATES

Businesswire | March 29, 2023

news image

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a strategic collaboration agreement with Novartis to develop, manufacture and commercialize Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets. “This collaboration builds on the groundbreaking clinical work we have been doing in the...

Read More

MedTech, Industry Outlook

MISSION BIO LAUNCHES TAPESTRI V3 TO RAPIDLY ACCELERATE RARE CELL DETECTION APPLICATIONS FOR TRANSLATIONAL RESEARCH AND PRECISION THERAPEUTICS

PRNewswire | June 01, 2023

news image

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications. With Tapestri® v3 chemistry, researchers can discover tiny numbers of single cells that, until now, easily escaped detection and influenced disease in invisible ways. At the same time, drug developers can use the new capabiliti...

Read More
news image

Medical

WUXI ATU AND WUGEN ANNOUNCE MANUFACTURING PARTNERSHIP TO EXPEDITE THE DELIVERY OF NOVEL CELL CANCER IMMUNOTHERAPIES

Wugen | June 16, 2022

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...

Read More
news image

Industrial Impact

MODERNA AND THERMO FISHER SCIENTIFIC ANNOUNCE LONG-TERM STRATEGIC COLLABORATION

Moderna, Inc. | February 24, 2022

Moderna, Inc. a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Thermo Fisher Scientific Inc. the world leader in serving science, today announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax®, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline. “Thermo Fisher continues to be a trusted partner, bringing a ...

Read More
news image

Industrial Impact, Medical

BICYCLE THERAPEUTICS ANNOUNCES A STRATEGIC COLLABORATION WITH NOVARTIS TO DISCOVER, DEVELOP AND COMMERCIALIZE BICYCLE® RADIO-CONJUGATES

Businesswire | March 29, 2023

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a strategic collaboration agreement with Novartis to develop, manufacture and commercialize Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets. “This collaboration builds on the groundbreaking clinical work we have been doing in the...

Read More
news image

MedTech, Industry Outlook

MISSION BIO LAUNCHES TAPESTRI V3 TO RAPIDLY ACCELERATE RARE CELL DETECTION APPLICATIONS FOR TRANSLATIONAL RESEARCH AND PRECISION THERAPEUTICS

PRNewswire | June 01, 2023

Mission Bio, Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced breakthrough improvements to the Tapestri® Platform and its core chemistry that enable highly confident detection of rare cells for a range of applications. With Tapestri® v3 chemistry, researchers can discover tiny numbers of single cells that, until now, easily escaped detection and influenced disease in invisible ways. At the same time, drug developers can use the new capabiliti...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us